Democrats in the U.S. Congress tried to stop a federal investigation into abortion pills—but they failed.
Despite babies dying from abortion drugs and growing reports of women being harmed, many anti-Life politicians continue to fight for the pills to stay on the market, no matter the risks.
A key group in Congress—the House Appropriations Committee—said they support the FDA taking a closer look at mifepristone in a meeting in June. The committee included this directive in a government funding bill for next year. They also told the FDA to report back within 30 days after the review is complete and share if any new rules or changes are needed.
Representative Riley Moore weighed in on social media:
Moore brought attention to the tragic deaths of Amber Thurman and Alyona Dixon, two women who reportedly died from complications linked to abortion pills. Although Amber Thurman’s own lawyer admitted in court that Pro-Life laws did not cause her death, some Democrats have distorted her story to push that false narrative—scaring doctors and ignoring what’s really putting women at risk.
“It’s ironic that the party that claims to care about women would block the FDA from following the science and adjusting to the new data,” Moore said.
The Ethics and Public Policy Center recently released The Abortion Pill Harms Women, the largest-ever study on abortion drugs. The study reviewed 865,727 mifepristone abortions from 2017 to 2023 and followed HIPAA regulations.
Shockingly, the researchers found that serious negative events from the abortion pill happen about 22 times more than the Food and Drug Administration (FDA) reports. Within 45 days of having an abortion, about 1 in 10 women experienced serious or life-threatening problems like severe bleeding, infection, or sepsis. This is a huge difference from what the FDA’s current drug label says—that fewer than 1 in 200 women would face such issues—based on studies done more than 40 years ago.
Story continues below.
Don’t miss awesome Pro-Life stories like this.
>> Get the Pro-Life Weekly Highlight just once a week:
Democrats have tried to discredit concerns about the abortion pill by saying many of the studies come from Pro-Life medical experts. But Representative Andy Harris pushed back:
“Many of the [pro-mifepristone] studies are done by institutions that actually profit from abortion,” he said. “You don’t dismiss that. You look at the quality of the data.”
“The FDA should always be available to do post-marketing surveillance,” Harris added. “That’s exactly why you have an FDA.”
With the FDA now expected to move forward with its review, the spotlight is once again on the safety of abortion pills—and whether politics should ever stand in the way of protecting women and children.
Back in May, RFK Jr. said he supported a full investigation into mifepristone.
“You have previously testified to the committee that you would do a top-to-bottom review of mifepristone,” Senator Josh Hawley said during a hearing. “Do you continue to stand by that, and don’t you think this new data shows that the need to do a review is in fact very pressing?”
RFK Jr. replied:
“I have asked Marty Makary, who is the director of FDA, to do a complete review and to report back.”
This new development marks a critical step forward in the fight to protect both women and their preborn children. We’re grateful for the leaders demanding accountability and truth. Every woman deserves real care, and every child deserves a chance at Life. This review gives hope that facts will prevail—and that more babies will be saved.
Thank you for reading this story! If you support our Pro-Life ministry, chip in with a life-saving contribution today!
